Abstract
The document associated with this DOI has been withdrawn.
Highlights
Osteonecrosis of the Jaw (ONJ) - related to Bisphosphonates (BPs), denosumab, and other drugs - is a bone disease, that should be evaluated on base of clinical features and by imaging tools, mostly Computed Tomography (CT) or Cone Beam Computed Tomography (CBCT)
We evaluated CT scans of patients treated with denosumab, developing ONJ
“Late signs” included: oro-antral fistula; pathologic fracture; prominence of the inferior alveolar nerve canal; osteolysis extending to the sinus floor; diffuse osteosclerosis; osteosclerosis of adjacent bones; periosteal reaction; sinusitis
Summary
Osteonecrosis of the Jaw (ONJ) - related to Bisphosphonates (BPs), denosumab, and other drugs - is a bone disease, that should be evaluated on base of clinical features (bone exposure and other signs or symptoms) and by imaging tools, mostly Computed Tomography (CT) or Cone Beam Computed Tomography (CBCT). Methods: We reviewed relevant images at ONJ sites of patients developing ONJ after zoledronic acid or denosumab treatment, looking for presence of radiological alteration signs, described by Bedogni et al[4] and included in ONJ management recommendations by Italian Societies of Oral Medicine (SIPMO) and Maxillofacial Surgery (SICMF)[5][6] .
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
